| Type |
Details |
Score |
| Publication |
| First Author: |
Altman MK |
| Year: |
2021 |
| Journal: |
Development |
| Title: |
TRPM7 is a crucial regulator of pancreatic endocrine development and high-fat-diet-induced ?-cell proliferation. |
| Volume: |
148 |
| Issue: |
16 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Wan L |
| Year: |
2023 |
| Journal: |
Cancer Discov |
| Title: |
Splicing Factor SRSF1 Promotes Pancreatitis and KRASG12D-Mediated Pancreatic Cancer. |
| Volume: |
13 |
| Issue: |
7 |
| Pages: |
1678-1695 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Horii T |
| Year: |
2017 |
| Journal: |
Sci Rep |
| Title: |
Efficient generation of conditional knockout mice via sequential introduction of lox sites. |
| Volume: |
7 |
| Issue: |
1 |
| Pages: |
7891 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Ortiz JA |
| Year: |
2024 |
| Journal: |
Diabetes |
| Title: |
Trefoil Factor 2 Expressed by the Murine Pancreatic Acinar Cells Is Required for the Development of Islets and for ?-Cell Function During Aging. |
| Volume: |
73 |
| Issue: |
9 |
| Pages: |
1447-1461 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Antonucci L |
| Year: |
2015 |
| Journal: |
Proc Natl Acad Sci U S A |
| Title: |
Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress. |
| Volume: |
112 |
| Issue: |
45 |
| Pages: |
E6166-74 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Murakami S |
| Year: |
2019 |
| Journal: |
Dev Cell |
| Title: |
A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas. |
| Volume: |
51 |
| Issue: |
1 |
| Pages: |
113-128.e9 |
|
•
•
•
•
•
|
| Strain |
| Attribute String: |
coisogenic, mutant strain, transgenic |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Myt1/Myt1 Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129 * C57BL/6 * CBA * CD-1 * SJL |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Brca2/Brca2 Kras/Kras<+> Trp53/Trp53<+> Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Brca2/Brca2 Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kras/Kras<+> Pten/Pten<+> Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129S4/SvJae * BALB/c * C57BL/6 |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kras/Kras<+> Pten/Pten Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cdkn2a/Cdkn2a<+> Kras/Kras<+> Trp53/Trp53 Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129 * C57BL/6 * CBA * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cdkn2a/Cdkn2a Kras/Kras<+> Trp53/Trp53 Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129 * C57BL/6 * CBA * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cdkn2a/Cdkn2a<+> Kras/Kras<+> Trp53/Trp53<+> Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129 * C57BL/6 * CBA * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cdkn2a/Cdkn2a Kras/Kras<+> Trp53/Trp53<+> Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129 * C57BL/6 * CBA * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kras/Kras<+> Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Tg(Pdx1-cre)6Tuv/? TgTn(sb-T2/Onc)#Dla/? |
| Background: |
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Brca1/Brca1 Kras/Kras<+> Trp53/Trp53 Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S4/SvJae * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Brca1/Brca1 Kras/Kras<+> Trp53/Trp53 Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S4/SvJae * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/? Tg(Pdx1-cre)6Tuv/? Tg(tetO-MYC)36Bop/? |
| Background: |
involves: 129P2/OlaHsd * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cdkn2a/Cdkn2a<+> Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/? Tg(Pdx1-cre)6Tuv/? Tg(tetO-MYC)36Bop/? |
| Background: |
involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cish/Cish Tg(Ins1-EGFP)1Hara/? Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: C57BL/6 * CBA * CD-1 |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kras/Kras<+> Tg(CAG-Bgeo,-tsA58T)T26Ichi/? Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/? Tg(Pdx1-cre)6Tuv/? |
| Background: |
B6.Cg-Gt(ROSA)26Sor Tg(Pdx1-cre)6Tuv |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? Trp53/Trp53 |
| Background: |
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kras/Kras<+> Rab11fip1/Rab11fip1 Tg(Pdx1-cre)6Tuv/? Trp53/Trp53<+> |
| Background: |
involves: 129S4/SvJae * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Epha2/Epha2 Kras/Kras<+> Trp53/Trp53<+> Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S/SvEv * 129S4/SvJae * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Kras/Kras<+> Prdm1/Prdm1 Tg(Pdx1-cre)6Tuv/? Trp53/Trp53<+> |
| Background: |
involves: 129 * C57BL/6NCrl * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? Trp53/Trp53<+> |
| Background: |
involves: 129 * C57BL/6NCrl * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cd9/Cd9<+> Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? Trp53/Trp53<+> |
| Background: |
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6N * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? Trp53/Trp53<+> |
| Background: |
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? Trp53/Trp53 |
| Background: |
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Cdk8/Cdk8 Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: C57BL/6N * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? Trp53/Trp53<+> |
| Background: |
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Trim29/Trim29 Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: C57BL/6N * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Tg(Pdx1-cre)89.1Dam/? Trim29/Trim29 |
| Background: |
involves: 129 * C57BL/6 * CBA |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Acaa1a/Acaa1a<+> Kras/Kras<+> Trp53/Trp53<+> Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S4/SvJae * C57BL/6 * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gata4/Gata4 Gata6/Gata6 Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S1/Sv * 129X1/SvJ * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gata4/Gata4<+> Gata6/Gata6<+> Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S1/Sv * 129X1/SvJ * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gata4/Gata4<+> Gata6/Gata6 Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S1/Sv * 129X1/SvJ * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Lats1/Lats1 Lats2/Lats2 Tg(Pdx1-cre)89.1Dam/? Wwtr1/Wwtr1<+> Yap1/Yap1 |
| Background: |
involves: 129S6/SvEvTac * 129S/SvEv * C57BL/6Brd * CBA * CD-1 |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gata4/Gata4 Gata6/Gata6<+> Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S1/Sv * 129X1/SvJ * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Dpy30/Dpy30 Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: C57BL/6 * C57BL/6N * CBA |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Tg(Pdx1-flpo)#Ybi/? |
| Background: |
involves: 129S6/SvEvTac |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Myt1/Myt1 Myt1l/Myt1l St18/St18 Tg(Ins1-EGFP)1Hara/? Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129S6/SvEvTac * C57BL/6 * CBA * CD-1 |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Ccpg1/Ccpg1 Kras/Kras<+> Tg(Pdx1-cre)6Tuv/? |
| Background: |
involves: 129S4/SvJae * C57BL/6N * FVB/N |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Genotype |
| Symbol: |
Gt(ROSA)26Sor/Gt(ROSA)26Sor<+> Mirc20/Mirc20 Tg(Pdx1-cre)89.1Dam/? |
| Background: |
involves: 129 * C57BL/6 * CBA |
| Zygosity: |
cn |
| Has Mutant Allele: |
true |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
672
 |
| Fragment?: |
false |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
218
 |
| Fragment?: |
true |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
220
 |
| Fragment?: |
false |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
448
 |
| Fragment?: |
true |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
244
 |
| Fragment?: |
false |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
200
 |
| Fragment?: |
false |
|
•
•
•
•
•
|
| Protein |
| Organism: |
Mus musculus/domesticus |
| Length: |
200
 |
| Fragment?: |
false |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Su H |
| Year: |
2021 |
| Journal: |
Cancer Cell |
| Title: |
Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. |
| Volume: |
39 |
| Issue: |
5 |
| Pages: |
678-693.e11 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Renz BW |
| Year: |
2018 |
| Journal: |
Cancer Cell |
| Title: |
?2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. |
| Volume: |
33 |
| Issue: |
1 |
| Pages: |
75-90.e7 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Schmiechen ZC |
| Year: |
2026 |
| Journal: |
Sci Immunol |
| Title: |
T(reg) cells promote immunotherapy-induced immune evasion by restraining CD4 T cell control of MHC-I-deficient metastatic pancreatic cancer. |
| Volume: |
11 |
| Issue: |
120 |
| Pages: |
eadz4302 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Zhang Y |
| Year: |
2013 |
| Journal: |
Cancer Res |
| Title: |
Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. |
| Volume: |
73 |
| Issue: |
20 |
| Pages: |
6359-74 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Peran I |
| Year: |
2021 |
| Journal: |
Gastroenterology |
| Title: |
Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. |
| Volume: |
160 |
| Issue: |
4 |
| Pages: |
1359-1372.e13 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Baird JR |
| Year: |
2016 |
| Journal: |
Cancer Res |
| Title: |
Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors. |
| Volume: |
76 |
| Issue: |
1 |
| Pages: |
50-61 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Alam MS |
| Year: |
2024 |
| Journal: |
Cell Rep Med |
| Title: |
TNFR1 signaling promotes pancreatic tumor growth by limiting dendritic cell number and function. |
| Volume: |
5 |
| Issue: |
9 |
| Pages: |
101696 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Liu M |
| Year: |
2025 |
| Journal: |
Nat Genet |
| Title: |
Tracing the evolution of single-cell 3D genomes in Kras-driven cancers. |
| Volume: |
57 |
| Issue: |
12 |
| Pages: |
3075-3087 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Isermann T |
| Year: |
2021 |
| Journal: |
Nat Commun |
| Title: |
Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. |
| Volume: |
12 |
| Issue: |
1 |
| Pages: |
4019 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Lasse Opsahl EL |
| Year: |
2026 |
| Journal: |
Cancer Res |
| Title: |
Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation. |
| Volume: |
86 |
| Issue: |
1 |
| Pages: |
22-39 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Mello SS |
| Year: |
2017 |
| Journal: |
Cancer Cell |
| Title: |
A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. |
| Volume: |
32 |
| Issue: |
4 |
| Pages: |
460-473.e6 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Sharon N |
| Year: |
2019 |
| Journal: |
Cell Rep |
| Title: |
Wnt Signaling Separates the Progenitor and Endocrine Compartments during Pancreas Development. |
| Volume: |
27 |
| Issue: |
8 |
| Pages: |
2281-2291.e5 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
P?rez-Mancera PA |
| Year: |
2012 |
| Journal: |
Nature |
| Title: |
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. |
| Volume: |
486 |
| Issue: |
7402 |
| Pages: |
266-70 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Liko D |
| Year: |
2019 |
| Journal: |
Cell Death Differ |
| Title: |
Brf1 loss and not overexpression disrupts tissues homeostasis in the intestine, liver and pancreas. |
| Volume: |
26 |
| Issue: |
12 |
| Pages: |
2535-2550 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Chiou SH |
| Year: |
2017 |
| Journal: |
Cancer Discov |
| Title: |
BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. |
| Volume: |
7 |
| Issue: |
10 |
| Pages: |
1184-1199 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Lee JJ |
| Year: |
2014 |
| Journal: |
Proc Natl Acad Sci U S A |
| Title: |
Stromal response to Hedgehog signaling restrains pancreatic cancer progression. |
| Volume: |
111 |
| Issue: |
30 |
| Pages: |
E3091-100 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Nielsen SR |
| Year: |
2016 |
| Journal: |
Nat Cell Biol |
| Title: |
Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis. |
| Volume: |
18 |
| Issue: |
5 |
| Pages: |
549-60 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Court H |
| Year: |
2013 |
| Journal: |
J Clin Invest |
| Title: |
Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. |
| Volume: |
123 |
| Issue: |
11 |
| Pages: |
4681-94 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Khalaileh A |
| Year: |
2013 |
| Journal: |
Cancer Res |
| Title: |
Phosphorylation of ribosomal protein S6 attenuates DNA damage and tumor suppression during development of pancreatic cancer. |
| Volume: |
73 |
| Issue: |
6 |
| Pages: |
1811-20 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Hermann PC |
| Year: |
2014 |
| Journal: |
Gastroenterology |
| Title: |
Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. |
| Volume: |
147 |
| Issue: |
5 |
| Pages: |
1119-33.e4 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Alam A |
| Year: |
2022 |
| Journal: |
Cancer Cell |
| Title: |
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. |
| Volume: |
40 |
| Issue: |
2 |
| Pages: |
153-167.e11 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Chiou SH |
| Year: |
2018 |
| Journal: |
Sci Rep |
| Title: |
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. |
| Volume: |
8 |
| Issue: |
1 |
| Pages: |
14008 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Ruscetti M |
| Year: |
2020 |
| Journal: |
Cell |
| Title: |
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer. |
| Volume: |
181 |
| Issue: |
2 |
| Pages: |
424-441.e21 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Klimovich B |
| Year: |
2022 |
| Journal: |
Oncogene |
| Title: |
p53 partial loss-of-function mutations sensitize to chemotherapy. |
| Volume: |
41 |
| Issue: |
7 |
| Pages: |
1011-1023 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Viale A |
| Year: |
2014 |
| Journal: |
Nature |
| Title: |
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. |
| Volume: |
514 |
| Issue: |
7524 |
| Pages: |
628-32 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Mueller S |
| Year: |
2018 |
| Journal: |
Nature |
| Title: |
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. |
| Volume: |
554 |
| Issue: |
7690 |
| Pages: |
62-68 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Cheung EC |
| Year: |
2020 |
| Journal: |
Cancer Cell |
| Title: |
Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer. |
| Volume: |
37 |
| Issue: |
2 |
| Pages: |
168-182.e4 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Kim MP |
| Year: |
2021 |
| Journal: |
Cancer Discov |
| Title: |
Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis. |
| Volume: |
11 |
| Issue: |
8 |
| Pages: |
2094-2111 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Wang Z |
| Year: |
2020 |
| Journal: |
Cancer Cell |
| Title: |
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy. |
| Volume: |
37 |
| Issue: |
6 |
| Pages: |
834-849.e13 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Ferguson LP |
| Year: |
2023 |
| Journal: |
Nat Commun |
| Title: |
Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma. |
| Volume: |
14 |
| Issue: |
1 |
| Pages: |
292 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Kinsey C |
| Year: |
2014 |
| Journal: |
Cell Rep |
| Title: |
Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression. |
| Volume: |
7 |
| Issue: |
4 |
| Pages: |
1143-55 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Kidger AM |
| Year: |
2022 |
| Journal: |
Oncogene |
| Title: |
Suppression of mutant Kirsten-RAS (KRAS(G12D))-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6. |
| Volume: |
41 |
| Issue: |
20 |
| Pages: |
2811-2823 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Mazur PK |
| Year: |
2010 |
| Journal: |
Proc Natl Acad Sci U S A |
| Title: |
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. |
| Volume: |
107 |
| Issue: |
30 |
| Pages: |
13438-43 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Carpenter AC |
| Year: |
2010 |
| Journal: |
Genesis |
| Title: |
Generation of mice with a conditional null allele for Wntless. |
| Volume: |
48 |
| Issue: |
9 |
| Pages: |
554-8 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Baumgartner BK |
| Year: |
2014 |
| Journal: |
Dev Biol |
| Title: |
Distinct requirements for beta-catenin in pancreatic epithelial growth and patterning. |
| Volume: |
391 |
| Issue: |
1 |
| Pages: |
89-98 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Tiano JP |
| Year: |
2011 |
| Journal: |
J Clin Invest |
| Title: |
Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents ? cell failure in rodent models of type 2 diabetes. |
| Volume: |
121 |
| Issue: |
8 |
| Pages: |
3331-42 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Khant Aung Z |
| Year: |
2021 |
| Journal: |
Front Endocrinol (Lausanne) |
| Title: |
Prolactin-Induced Adaptation in Glucose Homeostasis in Mouse Pregnancy Is Mediated by the Pancreas and Not in the Forebrain. |
| Volume: |
12 |
|
| Pages: |
765976 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Yoshihara E |
| Year: |
2016 |
| Journal: |
Cell Metab |
| Title: |
ERR? Is Required for the Metabolic Maturation of Therapeutically Functional Glucose-Responsive ??Cells. |
| Volume: |
23 |
| Issue: |
4 |
| Pages: |
622-34 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Chamberlain CE |
| Year: |
2014 |
| Journal: |
J Clin Invest |
| Title: |
Menin determines K-RAS proliferative outputs in endocrine cells. |
| Volume: |
124 |
| Issue: |
9 |
| Pages: |
4093-101 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Wu Z |
| Year: |
2015 |
| Journal: |
J Neurosci |
| Title: |
GABAergic projections from lateral hypothalamus to paraventricular hypothalamic nucleus promote feeding. |
| Volume: |
35 |
| Issue: |
8 |
| Pages: |
3312-8 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Sun C |
| Year: |
2022 |
| Journal: |
Dis Model Mech |
| Title: |
Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas. |
| Volume: |
15 |
| Issue: |
8 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Higashiyama H |
| Year: |
2017 |
| Journal: |
Development |
| Title: |
Embryonic cholecystitis and defective gallbladder contraction in the Sox17-haploinsufficient mouse model of biliary atresia. |
| Volume: |
144 |
| Issue: |
10 |
| Pages: |
1906-1917 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Gams A |
| Year: |
2023 |
| Journal: |
Physiol Rep |
| Title: |
Evidence of sex differences in cancer-related cardiac complications in mouse models of pancreatic and liver cancer. |
| Volume: |
11 |
| Issue: |
8 |
| Pages: |
e15672 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Pitarresi JR |
| Year: |
2018 |
| Journal: |
Life Sci Alliance |
| Title: |
Disruption of stromal hedgehog signaling initiates RNF5-mediated proteasomal degradation of PTEN and accelerates pancreatic tumor growth. |
| Volume: |
1 |
| Issue: |
5 |
| Pages: |
e201800190 |
|
•
•
•
•
•
|
| Publication |
| First Author: |
Stellas D |
| Year: |
2014 |
| Journal: |
J Natl Cancer Inst |
| Title: |
Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. |
| Volume: |
106 |
| Issue: |
12 |
|
|
•
•
•
•
•
|
| Publication |
| First Author: |
Markosyan N |
| Year: |
2019 |
| Journal: |
J Clin Invest |
| Title: |
Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). |
| Volume: |
129 |
| Issue: |
9 |
| Pages: |
3594-3609 |
|
•
•
•
•
•
|